ALINT.PA stock up 22% intraday on EURONEXT: volume spike offers key setup

ALINT.PA stock jumped 22.03% intraday on 24 Mar 2026, trading at EUR 0.18 on EURONEXT after a burst of buying volume. Volume climbed to 48,897 shares versus a 3-month average of 12,329, driving the price from an open of EUR 0.1505 to a session high of EUR 0.19. The move snapped a short-term downtrend and put ALINT.PA back above its 50-day average of EUR 0.16. We examine whether the volume spike reflects a genuine technical rebound or a short-lived momentum trade for this France-based biotechnology services provider.

Intraday price and volume drivers for ALINT.PA stock

The immediate driver for ALINT.PA stock was a surge in intraday orders that lifted the price to EUR 0.18, up EUR 0.03 from the prior close of EUR 0.1475. Average volume over the session was 48,897, nearly 4.0x the 50-day average of 12,329, a classic high-volume mover signal. Traders cited positioning around the stock’s 50-day average (EUR 0.16297) and a short-term oversold technical picture as catalysts for the spike.

Fundamentals and valuation view on ALINT.PA stock

IntegraGen SA (ALINT.PA) operates in Biotechnology on EURONEXT in Europe, with market cap EUR 991,019.00 and 6,606,796 shares outstanding. Trailing EPS is -0.04 and the reported PE is -3.75, reflecting losses. Price-to-sales is 0.15 and price-to-book is 2.93, signaling low revenue valuation but limited equity cushion amid negative margins.

Technical setup and risk signals for ALINT.PA stock

Technicals show mixed signals: RSI at 38.19 and CCI at -191.94 point to an oversold condition that can attract bounce buyers. Bollinger bands sit 0.15–0.19, matching the day range, while ADX at 14.61 indicates no clear trend. Traders should note thin liquidity historically: year low EUR 0.115 and year high EUR 0.73 imply wide range risk.

Meyka AI grade and model forecast for ALINT.PA stock

Meyka AI rates ALINT.PA with a score out of 100: 61.47 / 100 — Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target of EUR 0.17, versus the current price of EUR 0.18, implying a near-term downside of -5.56%. Forecasts are model-based projections and not guarantees.

Sector context and peer comparison for ALINT.PA stock

IntegraGen sits in Healthcare, Biotechnology on EURONEXT where the sector 3M performance is -3.08%. Compared with sector averages — price-to-sales 7.58 and PB around 2.59 — ALINT.PA’s price-to-sales 0.15 is materially lower, reflecting its small size and negative margins. The stock’s debt-to-equity 1.23 and current ratio 1.19 add liquidity risk versus larger biotech peers.

Trading strategy and short-term outlook for ALINT.PA stock

For intraday and short-term traders, the volume spike and move above the 50-day average create a momentum setup, but volatility is high. Use tight risk controls: stop-loss near EUR 0.15 or below the session low EUR 0.1505. Swing traders should watch confirmation above EUR 0.19 and improvements in daily volume. Longer-term investors should require earnings improvement and margin stabilization.

Final Thoughts

ALINT.PA stock delivered a significant intraday move on 24 Mar 2026, rising 22.03% to EUR 0.18 on EURONEXT as volume jumped to 48,897 shares. The spike cleared the 50-day average and produced a short-term technical setup for momentum traders, but fundamentals remain mixed: EPS -0.04, PE negative, and debt-to-equity 1.23. Meyka AI’s model projects a monthly target of EUR 0.17, implying a modest -5.56% downside from today’s price, and our Meyka AI grade of 61.47/100 (B, HOLD) reflects balanced near-term opportunity and medium-term risk. Investors should treat today’s move as a tactical event: intraday traders can trade the volatility with strict stops, while longer-term holders should wait for clearer earnings and cash-flow improvement. Meyka AI provides this AI-powered market analysis to help frame the intraday move within financial and technical context

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.